Compass Pathways (CMPS)

Executive Summary

Compass Pathways is a publicly traded biotechnology company pioneering evidence-based psilocybin therapy for severe mental health conditions, with its lead program COMP360 in phase 3 development for treatment-resistant depression (TRD). The company leverages a proprietary formulation of psilocybin combined with psychological support, targeting a significant unmet need in patients who fail to respond to existing antidepressants. With a strong safety profile and promising phase 2b results, Compass is positioned to disrupt the mental health treatment paradigm. Beyond TRD, the company is expanding into PTSD and anorexia nervosa, addressing large market opportunities. Despite high clinical and regulatory risks, the potential for first-in-class approval drives its investment thesis.

Upcoming Catalysts (preview)

• Q3 2026COMP360 Phase 3 Topline Results in TRD55% success
• Q2 2026Phase 2 Data Readout for PTSD50% success
• Q3 2026FDA Breakthrough Therapy Designation Update or Regulatory Meeting Outcomes70% success